Big Pharma's Comeback Is Here: Winners, Losers, And 4 ETFs

ALLKA Research 3.56K Followers Follow Summary Nine of the 16 Big Pharma stocks covered in this article set new 52-week highs during August, reflecting strong momentum across the sector. Also, the rally has been driven by strong Q2 results, as well as Wall Street’s growing shift toward healthcare amid continued geopolitical tensions in the Middle East. By contrast, Sanofi and AstraZeneca remain out of favor with the market, despite double-digit sales growth at key blockbusters such as Dupixent, Imfinzi, and Enhertu. In my view, this may partly reflect the growing controversy around vaccines fueled by HHS Secretary RFK Jr. and claims about their alleged link to autism. In this article, I will also analyze four key healthcare ETFs and identify which one, in my view, offers the most attractive risk/reward profile for income-oriented investors. Gladkikh/iStock via Getty Images From the end of July through the first week of August, Big Pharma players reported their Q2 earnings. Some of them beat analyst consensus forecasts by a wide margin, but others fell short due to weaker This article was written by ALLKA Research 3.56K Followers Follow With over two decades of dedicated experience in investment, Allka Research has been a guiding force for individuals seeking lucrative opportunities. Its conservative approach sets it apart, consistently unearthing undervalued assets within the realms of ETFs, commodities, technology, and pharmaceutical companies.Allka Research's journey in the investment landscape is marked by a commitment to delivering substantial returns and strategic insights to its clients. In a world filled with complexities, Allka Research thrives on simplifying investment strategies, ensuring accessibility for both seasoned investors and those just starting.Driven by an unwavering passion for empowering others financially, Allka Research seeks to share its wealth of knowledge through Seeking Alpha. Its mission is to contribute thought-provoking analyses and informed perspectives to the Seeking Alpha community. With a desire to demystify the intricacies of investing, Allka Research aims to inspire confidence in its readers, fostering a community of informed investors who can navigate the markets with intelligence and understanding. Join Allka Research on this exciting journey of discovery and wealth creation as it continues to unravel the secrets of the financial world on Seeking Alpha. Analyst’s Disclosure: I/we have a beneficial long position in the shares of ALVO either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.